본 보고서에서는 버킷 림프종의 상세한 이해, 과거 및 미래의 역학 데이터, 미국, EU 4개국(독일, 프랑스, 이탈리아, 스페인), 영국, 일본에서의 버킷 림프종 시장 동향을 종합적으로 분석하고, 현재의 치료의 실천, 새롭게 등장하는 치료제, 각 치료법 시장 점유율, 2020년부터 2034년에 걸친 시장 규모 추이와 예측을 주요 7개 시장마다 제시하고 있습니다. 또한 현행 버킷 림프종 치료 프로토콜과 알고리즘, 미충족 요구에 대해서도 다루어 향후 시장 기회를 명확히 하고 그 잠재적 성장력을 평가했습니다.
DelveInsight's "Burkitt lymphoma - Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Burkitt lymphoma, historical and forecasted epidemiology, as well as the Burkitt lymphoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Burkitt lymphoma market report provides current treatment practices, emerging drugs, Burkitt lymphoma share of individual therapies, and current and forecasted Burkitt lymphoma market size from 2020 to 2034, segmented by seven major markets. The report also covers current Burkitt lymphoma treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Study Period: 2020-2034
Burkitt Lymphoma Overview
Burkitt lymphoma is a highly aggressive, fast-growing B-cell non-Hodgkin lymphoma characterized by translocations involving the MYC oncogene. It has three main subtypes: endemic, sporadic, and immunodeficiency-related, and often presents with rapidly enlarging tumors in the jaw, abdomen, or other extranodal sites. Though rare (about 1-5% of all NHL cases), it is considered a medical emergency due to its rapid progression, but it is also highly responsive to intensive, short-course chemotherapy regimens, often with cure rates exceeding 80% in children when treated promptly.
Burkitt Lymphoma Diagnosis
Burkitt lymphoma is a highly aggressive and rapidly progressing type of non-Hodgkin lymphoma that demands urgent and accurate diagnosis to initiate timely treatment. Since symptoms often appear suddenly and worsen quickly, early detection is vital. Doctors typically begin with a physical examination to look for swollen lymph nodes or abdominal swelling. Diagnostic confirmation is usually made through a biopsy of the affected tissue, while blood tests help assess white blood cell counts, lactate dehydrogenase (LDH) levels, and organ function.
To determine the extent of disease, imaging tests such as CT, PET, or MRI scans are used, along with bone marrow biopsies to check for spread into the bone marrow. In some cases, especially in children or high-risk patients, a lumbar puncture may also be done to evaluate central nervous system involvement. Because Burkitt lymphoma grows so rapidly, treatment is often started immediately after diagnosis, sometimes even before staging is complete. Receiving a prompt and precise evaluation from a lymphoma specialist plays a critical role in improving patient outcomes.
Burkitt Lymphoma Treatment
Since Burkitt lymphoma is very aggressive, the diagnosis of this disease requires urgent hospitalization and the immediate start of therapy. However, Burkitt lymphoma is often very responsive to the currently recommended intensive chemotherapy regimens, and cure rates for this disease remain high.
Treatment options are determined based on low versus high-risk status. The combination of agents used for low and high-risk diseases is similar, but high-risk patients are given additional treatment. All of the treatments used are intensive, using high doses of drugs given frequently.
Specific treatment options for adults include the regimens described below:
Different combination chemotherapy regimens are used to treat Burkitt lymphoma in children and adolescents. Younger patients tend to have excellent responses to chemotherapy and particularly high cure rates.
The Burkitt lymphoma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the Total prevalent cases of non-Hodgkin lymphoma, diagnosed prevalent cases of burkitt lymphoma, Gender-specific cases of burkitt lymphoma, Age-specific cases of burkitt lymphoma, Subtype-specific cases of burkitt lymphoma, and treatment-eligible pool in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.
Marketed Drugs
RITUXAN (rituximab): Genentech
RITUXAN in combination with chemotherapy is approved for use in pediatric patients aged six months and older with mature B-cell non-Hodgkin lymphoma and mature B-cell acute leukemia (B-AL). Its indication includes the treatment of previously untreated, advanced-stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia, when administered in combination with chemotherapy.
Emerging Drugs
Sepantronium Bromide (PC-002): Cothera Bioscience
PC-002 (also known as YM155, sepantronium bromide) is a first-in-class small molecule drug inhibitor of DUB, an enzyme family that removes ubiquitin from cellular proteins otherwise destined for degradation. With more than 50% of human cancers showing increased expression, Myc is regarded as one of the most important yet "undruggable" cancer targets. By inhibiting DUB that stabilizes the Myc protein in cancer cells, PC-002 selectively induces Myc protein degradation and cell apoptosis in Myc-dependent tumors. PC-002 may potentially target multiple cancer indications involving Myc dysregulation.
PC-002 is currently in Phase II studies for multiple indications, including burkitt lymphoma and DLBCL, and has demonstrated initial efficacy as well as safety in an ongoing monotherapy trial in relapsed and refractory high-grade B-cell lymphoma and Burkitt lymphoma patients with MYC rearrangement.
Drug Class Insight
In the marketed class of drugs, the cornerstone of therapy includes mitogen-activated protein kinase inhibitors such as COTELLIC.
The therapeutic landscape for Burkitt lymphoma remains dominated by intensive, short-course multi-agent chemotherapy regimens, often combined with the anti-CD20 monoclonal antibody rituximab in CD20-positive disease. Pediatric patients, particularly those with localized disease, typically achieve high cure rates, while adult cases, especially in older or comorbid populations, pose greater treatment challenges due to regimen-related toxicity.
Frontline management for advanced-stage Burkitt lymphoma generally involves dose-intensive protocols such as CODOX-M/IVAC or Hyper-CVAD, with rituximab now FDA-approved in pediatric advanced-stage CD20-positive Burkitt lymphoma. For relapsed or refractory disease, therapeutic options are limited and outcomes remain poor, with salvage regimens, high-dose chemotherapy, and hematopoietic stem cell transplantation representing the mainstay. Targeted therapy development is in its infancy, with early clinical evaluations of apoptosis-inducing agents (e.g., sepantronium bromide), cell-based immunotherapies (e.g., ACE1831), and other novel approaches underway. The emerging pipeline is relatively sparse, with most research focused on optimizing existing regimens, incorporating targeted antibodies, and exploring CAR-T cell therapy and bispecific antibodies for refractory settings. This reflects a market still anchored in curative-intent chemotherapy, with gradual movement toward precision and immunotherapy-based strategies for high-risk or treatment-resistant patients.
This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025-2034. The landscape of Burkitt lymphoma treatment has experienced a profound transformation with the uptake of novel drugs.
Burkitt Lymphoma Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, I stages. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for Burkitt lymphoma emerging therapies.
KOL- Views
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders like MD, Professor and Vice Chair of the Department of Medicine and Director, PhD, and others. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or Burkitt lymphoma market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Delveinsight's analysts connected with 15+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as the Washington University School of Medicine, University Medical Center Hamburg-Eppendorf, and University Graduate School of Medicine, etc., were contacted. Their opinion helps understand and validate Burkitt lymphoma epidemiology and market trends.
Qualitative Analysis
We perform qualitative and market intelligence analysis using various approaches, such as SWOT and conjoint analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
The analyst analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry.
In efficacy, the trial's primary and secondary outcome measures are evaluated.
Further, the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials.
Market Access and Reimbursement
Reimbursement may be referred to as the negotiation of a price between a manufacturer and a payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs) and third-party organizations that provide services and educational programs to aid patients are also present.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.